

Apotex plans expansion in India

31 July 2017 | News

The new office, located in Godrej & Boyce Business District, Vikhroli spans over 42,000 square feet and has been designed to maximize collaboration and employee engagement.



Apotex Research, an Indian subsidiary of global pharmaceutical company Apotex Inc., headquartered in Toronto Canada has announced a significant investment which will further expand its footprint in India.

The company has set up its Global Business Services office in Mumbai to provide centralized service delivery for various areas including Medical, Regulatory, Quality, Manufacturing, Administrative and Commercial functions for Apotex globally. In addition, the move will create 200 job openings.

The new office, located in Godrej & Boyce Business District, Vikhroli spans over 42,000 square feet and has been designed to maximize collaboration and employee engagement.

In 2004, Apotex Research and its sister company, Apotex Pharmachem were established in Bengaluru. Over the last 13 years, it evolved into one of Apotex's global strategic R&D and manufacturing centres with over 2,500 employees. Operations include API & Formulation R&D, Clinical Research, API and Finished Dose Manufacturing. The state-of the art campus in Bengaluru supplies products to the US, Canada, EU and Australia.

Apotex is Canada's largest privately held pharmaceutical company with a global presence in more than 45 countries with more than 11,000 employees. With its worldwide manufacturing sites, it can manufacture up to 25 billion dosages per year. It produces 300 medicines in 4,000 dosages and formats that are exported to 115 countries. The company will spend \$2 billion over the next 10 years on research and development.